Drug particulate

Drug particulates refer to mobile, undissolved substances, other than gas bubbles, unintentionally present in parenteral, ophthalmic, or inhalable drug products (USP <788>, 2021). This term does not describe a biological target molecule like a receptor or enzyme; rather, it identifies a physical quality attribute and safety hazard in pharmaceutical manufacturing (Langille, 2013). Particulates are categorized as extrinsic (foreign materials like glass or fibers), intrinsic (materials from manufacturing or packaging processes), or inherent (formulation-related materials such as protein aggregates) (Bukofzer et al., 2015). Clinically, particulates are significant because they can cause mechanical obstruction of small blood vessels, leading to phlebitis, granulomas, or systemic emboli (FDA, 2014). Furthermore, in the context of protein-based therapeutics, particulates and aggregates can act as potent immunological adjuvants that trigger the production of anti-drug antibodies, potentially reducing clinical efficacy and increasing the risk of hypersensitivity (Moussa et al., 2016).

Other names

Particulate matterInsoluble matterVisible particlesSub-visible particlesForeign particulate matterIntrinsic particulatesExtrinsic particulates

Not applicable. Drug particulates are physical contaminants that act via mechanical obstruction of blood vessels or by stimulating an immune response against the drug product.